Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mediators produced by the endothelial cell.

R J Gryglewski1, R M Botting, J R Vane

  • 1William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, UK.

Hypertension (Dallas, Tex. : 1979)
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relationship between the penetration of tryptamine and 5-hydroxytryptamine into smooth muscle and the associated contractions.

British journal of pharmacology and chemotherapy·2008
Same author

An analysis of the responses of the isolated portal vein of the rabbit to electrical stimulation and to drugs.

British journal of pharmacology and chemotherapy·2008
Same author

Adventures and excursions in bioassay: the stepping stones to prostacylin.

Bioscience reports·2005
Same author

The mechanism of action of aspirin.

Thrombosis research·2003
Same author

My life and times with enzymes and mediators.

Medical science monitor : international medical journal of experimental and clinical research·2001
Same author

The fight against rheumatism: from willow bark to COX-1 sparing drugs.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2001

Vascular endothelial cells produce three mediators to prevent blood clots and cell adhesion. These include prostacyclin, nitric oxide (formerly EDRF), and 13-hydroxy-9,11-octadecadienoic acid, forming a defense against vascular diseases.

Area of Science:

  • Biochemistry
  • Vascular Biology
  • Cellular Signaling

Background:

  • The endothelium maintains a non-thrombogenic surface through secreted mediators.
  • Vascular endothelial cells synthesize key signaling molecules that regulate blood clotting and cell adhesion.
  • Dysfunction of these endothelial defense mechanisms is implicated in cardiovascular diseases like hypertension and atherosclerosis.

Purpose of the Study:

  • To review the roles of three principal mediators synthesized by vascular endothelial cells.
  • To elucidate the mechanisms by which these mediators maintain endothelial non-thrombogenicity.
  • To explore the link between the breakdown of this endothelial defense and the pathogenesis of vascular diseases.

Main Methods:

  • Review of scientific literature on endothelial mediators and their functions.

Related Experiment Videos

  • Discussion of the chemical properties and biological activities of prostacyclin, EDRF (nitric oxide), and 13-hydroxy-9,11-octadecadienoic acid.
  • Analysis of the synergistic effects and intracellular actions of these mediators.

    • Main Results:

    • Prostacyclin, a metabolite of arachidonic acid, inhibits platelet aggregation and relaxes vascular smooth muscle.
    • Endothelium-derived relaxing factor (EDRF), identified as nitric oxide, also inhibits platelet aggregation and adhesion.
    • 13-Hydroxy-9,11-octadecadienoic acid acts intracellularly to reduce endothelial cell adhesiveness.

    Conclusions:

    • Prostacyclin and EDRF (nitric oxide) are released upon stimulation and work synergistically to prevent platelet aggregation.
    • These three mediators constitute a crucial endothelial defense system against blood-borne elements.
    • Impairment of this defense mechanism contributes to the development of hypertension and atherosclerosis.